BACKGROUND: To determine the maximum-tolerated duration and dose-limiting toxicity of a daily schedule of orally administered cyclophosphamide and topotecan in pediatric patients with recurrent or refractory malignant solid tumors. METHODS: Patients received oral cyclophosphamide (50 mg/m2/dose) in the morning followed by topotecan (0.8 mg/m2/dose) 8-12 hr later for an escalating number of consecutive days (10, 14, and 17 days). RESULTS: Seventeen pediatric patients were treated with oral cyclophosphamide and topotecan for durations of 10-17 days for a total of 58 treatment courses. Reversible hematologic toxicity (neutropenia and thrombocytopenia) was the dose-limiting toxicity. Nonhematologic toxicities of greater than grade 3 were not observed. A partial response (neuroblastoma following myeloablative chemotherapy and stem cell rescue) and prolonged stable disease (medulloblastoma) were each observed in one patient. CONCLUSIONS: The recommended duration of therapy with a daily schedule of both oral cyclophosphamide (50 mg/m2/day) and topotecan (0.8 mg/m2/day) for previously treated pediatric patients with recurrent or refractory solid tumors is 14 consecutive days. The observed dose limiting toxicity (DLT) was reversible neutropenia. This regimen was well tolerated in heavily pretreated patients and demonstrated activity against recurrent pediatric solid tumors. Copyright 2003 Wiley-Liss, Inc.
BACKGROUND: To determine the maximum-tolerated duration and dose-limiting toxicity of a daily schedule of orally administered cyclophosphamide and topotecan in pediatric patients with recurrent or refractory malignant solid tumors. METHODS:Patients received oral cyclophosphamide (50 mg/m2/dose) in the morning followed by topotecan (0.8 mg/m2/dose) 8-12 hr later for an escalating number of consecutive days (10, 14, and 17 days). RESULTS: Seventeen pediatric patients were treated with oral cyclophosphamide and topotecan for durations of 10-17 days for a total of 58 treatment courses. Reversible hematologic toxicity (neutropenia and thrombocytopenia) was the dose-limiting toxicity. Nonhematologic toxicities of greater than grade 3 were not observed. A partial response (neuroblastoma following myeloablative chemotherapy and stem cell rescue) and prolonged stable disease (medulloblastoma) were each observed in one patient. CONCLUSIONS: The recommended duration of therapy with a daily schedule of both oral cyclophosphamide (50 mg/m2/day) and topotecan (0.8 mg/m2/day) for previously treated pediatric patients with recurrent or refractory solid tumors is 14 consecutive days. The observed dose limiting toxicity (DLT) was reversible neutropenia. This regimen was well tolerated in heavily pretreated patients and demonstrated activity against recurrent pediatric solid tumors. Copyright 2003 Wiley-Liss, Inc.
Authors: Giles W Robinson; Vasilisa A Rudneva; Ivo Buchhalter; Catherine A Billups; Sebastian M Waszak; Kyle S Smith; Daniel C Bowers; Anne Bendel; Paul G Fisher; Sonia Partap; John R Crawford; Tim Hassall; Daniel J Indelicato; Frederick Boop; Paul Klimo; Noah D Sabin; Zoltan Patay; Thomas E Merchant; Clinton F Stewart; Brent A Orr; Jan O Korbel; David T W Jones; Tanvi Sharma; Peter Lichter; Marcel Kool; Andrey Korshunov; Stefan M Pfister; Richard J Gilbertson; Robert P Sanders; Arzu Onar-Thomas; David W Ellison; Amar Gajjar; Paul A Northcott Journal: Lancet Oncol Date: 2018-05-16 Impact factor: 41.316
Authors: Rachel Kennedy; Daniel Groepper; Michael Tagen; Robbin Christensen; Fariba Navid; Amar Gajjar; Clinton F Stewart Journal: Ann Pharmacother Date: 2010-01-26 Impact factor: 3.154
Authors: Kieuhoa T Vo; Erin E Karski; Nicole M Nasholm; Shelly Allen; Fabienne Hollinger; W Clay Gustafson; Janel R Long-Boyle; Stephen Shiboski; Katherine K Matthay; Steven G DuBois Journal: Oncotarget Date: 2017-04-04
Authors: Francisco Bautista; Victoria Fioravantti; Teresa de Rojas; Fernando Carceller; Luis Madero; Alvaro Lassaletta; Lucas Moreno Journal: Cancer Med Date: 2017-10-04 Impact factor: 4.452